Trial Profile
A Phase 1/2 Safety and Efficacy Study of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 26 Jul 2021
Price :
$35
*
At a glance
- Drugs Epacadostat (Primary) ; Pembrolizumab (Primary) ; Ragifilimab (Primary)
- Indications Malignant melanoma; Renal cell carcinoma; Solid tumours; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Incyte Biosciences International
- 01 Jul 2021 Status changed from completed to discontinued.
- 21 Jul 2020 Status changed from active, no longer recruiting to completed.
- 17 Apr 2020 Planned End Date changed from 1 Mar 2020 to 30 Jun 2020.